BioLineRx, Ltd. (BLRX)
-NasdaqCM 1.63 
0.05(2.98%) May 24, 3:59PM EDT
| Prev Close: | 1.68 |
|---|
| Open: | 1.68 |
|---|
| Bid: | N/A |
|---|
| Ask: | 1.71 x 9900 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.62 - 1.68 |
|---|
| 52wk Range: | 1.55 - 5.10 |
|---|
| Volume: | 35,635 |
|---|
| Avg Vol (3m): | 212,066 |
|---|
| Market Cap: | 34.88M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.00 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- AbbVie's Latest Drug Deal Marks A Shift In The Celiac Disease Therapeutics Fieldat Seeking Alpha(Mon, May 20)
- BioLineRx Enters into “At-The-Market” Offering Agreement with Stifel, Nicolaus & CompanyBusiness Wire(Fri, May 17)
- BioLineRx to Present at the Oppenheimer 14th Annual Israeli Conference on May 12thBusiness Wire(Thu, May 9)
- BioLineRx Reports First Quarter 2013 ResultsBusiness Wire(Tue, May 7)
- BioLineRx's BL-7010, for the Treatment of Celiac, to be Presented at Two Leading ConferencesBusiness Wire(Thu, May 2)
- BioLineRx Pipeline Returns To The Winner's Circleat Seeking Alpha(Wed, May 1)
- BioLineRx to Report First Quarter 2013 Results on May 7, 2013Business Wire(Tue, Apr 30)
- BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis CBusiness Wire(Mon, Apr 29)
- Positive Data on BioLineRx TreatmentZacks(Thu, Apr 18)
- 5 Stocks Under $10 Set to Soarat TheStreet(Thu, Apr 18)
- BioLineRx to Present at the 12th Annual Needham Healthcare Conference in New York on April 30, 2013Business Wire(Thu, Apr 18)
- BioLineRx Announces Positive Phase II Results for BL-7040, an Orally Available Treatment for Inflammatory Bowel DiseaseBusiness Wire(Wed, Apr 17)
- BioLineRx to Start BL-8040 StudyZacks(Tue, Apr 16)
- Oramed Pharmaceuticals Appoints New Chief Operating Officer and VP of Business DevelopmentPR Newswire(Tue, Apr 16)
- BioLineRx receives approval for Phase II clinical trial for leukemia candidatetheflyonthewall.com(Wed, Apr 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. The companys development pipeline consists of six clinical-stage therapeutic candidates, inc...
View More